Xenon Pharma holder plans $437,721 share sale

Xenon Pharmaceuticals Inc. (XENE) had an officer, Christopher Kenney, file a notice of proposed sale of company stock under Rule 144.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. (XENE) had an officer, Christopher Kenney, file a notice of proposed sale of company stock under Rule 144. The notice covers up to 7,068 common shares, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $437,721.24 and listing on NASDAQ. The shares are to be sold on or after 08/28/2026 and were acquired upon vesting of restricted and performance stock units from Xenon on 03/09/2026 and 03/12/2026.

Key Figures

Shares proposed to be sold: 7,068 shares of common stock Aggregate market value: $437,721.24 Proposed sale date: 08/28/2026 +2 more

5 metrics

Shares proposed to be sold 7,068 shares of common stock Number of Xenon Pharmaceuticals Inc. shares covered by the Rule 144 notice

Aggregate market value $437,721.24 Aggregate market value of the 7,068 common shares proposed to be sold

Proposed sale date 08/28/2026 Proposed date for sale of Xenon Pharmaceuticals Inc. common shares

First vesting date of stock units 03/09/2026 Date on which part of the restricted and performance stock units vested

Second vesting date of stock units 03/12/2026 Date on which additional restricted and performance stock units vested

Key Terms

Rule 144, restricted and performance stock units, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted and performance stock units financial

"The securities to be sold were acquired upon the vesting of restricted and performance stock units"

aggregate market value financial

"7068 | 437721.24 | 96840432 | 08/28/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sale did Xenon Pharmaceuticals Inc. (XENE) disclose in this Form 144?

Christopher Kenney filed to sell 7,068 shares of Xenon Pharmaceuticals Inc. common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC and are listed on NASDAQ.

How many XENE shares are covered by Christopher Kenney's planned Rule 144 sale?

The notice covers up to 7,068 common shares of Xenon Pharmaceuticals Inc. These shares were acquired upon the vesting of restricted and performance stock units granted by the issuer.

What is the aggregate market value of the XENE shares in the Form 144 filing?

The filing states an aggregate market value of $437,721.24 for the 7,068 common shares of Xenon Pharmaceuticals Inc. proposed to be sold under Rule 144.

When are the XENE shares proposed to be sold under this Form 144?

The proposed sale date for the Xenon Pharmaceuticals Inc. common shares is 08/28/2026, as indicated in the securities information section of the notice.

How and when did Christopher Kenney acquire the XENE shares to be sold?

The notice states that the securities to be sold were acquired upon the vesting of restricted and performance stock units on 03/09/2026 and 03/12/2026, granted by Xenon Pharmaceuticals Inc.

Which broker is handling the planned sale of XENE shares?

The planned sale will be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as listed in the Form 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:26 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:25 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001880129
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	XENON PHARMACEUTICALS INC
SEC File Number	001-36687
Address of Issuer	3650 Gilmore Way Burnaby BRITISH COLUMBIA, CANADA V5G4W8
Phone	6044843300
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER KENNEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7068	437721.24	96840432	08/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/09/2026	Restricted and Performance Stock Units	Issuer			7068	03/09/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted and performance stock units on 03/09/2026 and 03/12/2026.
Date of Notice	08/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Kenney
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)